- NLM Digital Collections - Crizanlizumab, voxelotor, and L-glutamine for sickle cell disease : effectiveness and valuePublication: [Boston, Massachusetts] : Institute for Clinical and Economic Review, March 12, 2020... Experienced at least 1 acute pain 3. PK (AUCtau) after NCT03474965 Enrollment: 100 crisis within preceding 12 ... dose as determined by medical history 4. PD (AUCtau) after Novartis Pharmaceuticals 4. If receiving HU/HC ...
- NLM Digital Collections - M4E(R2) : the CTD--efficacyPublication: Silver Spring, MD : Center for Drug Evaluation and Research, July 2017... 26-50) 120 ± 30 2 350 ± 40 AUC*: AUCTAU or AUCinf Cmin**: For multiple dose studies 44 ... exposure), area-under-curve (total exposure), clearance, and accumulation of the parent drug and its metabolites, in ...
2 results